We study how serum and mucosal antibodies protect mammalian hosts from microbial pathogens and toxins. We are interested in next-generation vaccines and adjuvants to combat biothreat agents and enteric diseases.

We use genetics and molecular biology to learn how coronaviruses, a family of RNA viruses including the agents that cause SARS and MERS, replicate their genetic material and assemble into virions during infection.

We study gene regulation in the context of bacterial pathogenesis, with a focus on two pathogens: Mycobacterium tuberculosis, the bacterium that causes TB, and Yersinia pestis, the etiologic agent of bubonic and pneumonic plague.

In the Bacteriology Laboratory, Dr. Mingle performs diagnostic reference testing, using both molecular and classical methods, for the detection of various pathogenic bacteria in New York State.

The laboratory uses applied research to investigate the latest technological advances and maintain the capabilities necessary to identify and characterize unusual bacterial pathogens and emerging infectious diseases. The laboratory develops new molecular assays for public health purposes.

We develop molecular diagnostic assays and reference testing for the detection and characterization of pathogenic bacteria and mycobacteria and to predict antibiotic resistance using real-time PCR and whole genome sequencing.

We study mosquito-borne arboviruses, focusing on vertical transmission and persistent arboviral infections in mosquitoes. We are also interested in determining the role of RNA-RNA recombination in virus evolution.

We investigate the influence of biofilm growth on the mechanisms of pathogenesis, persistence and drug tolerance in mycobacterial pathogens, with particular emphasis on Mycobacterium tuberculosis.

We focus on simplifying and automating published low-volume newborn screening tests in order to transform them into high-volume assays.

My research explores the molecular biology of bacterial viruses (bacteriophages) and other mobile genetic parasites with a focus on how they shape the ecology and evolution of bacteria.

We seek to understand bacterial communication by investigating how bacteria interpret autoinducers and elicit appropriate gene expression, and, more globally, to understand how all organisms decode environmental stimuli.

We develop and maintain robust ICP-MS methodologies to support both human biomonitoring studies and emergency preparedness.

We study human exposure to toxic metals/metalloids (biomonitoring) and long-lived nuclides (radiobioassay); and develop novel speciation methods by coupling LC and GC to ICP-MS, while using portable XRF for field-based studies.

We study the molecular mechanisms by which multiple DNA polymerases replicate bacterial genomes completely, with high accuracy and tolerance for DNA damage, yet also create mutations that give rise to antibiotic resistance.

The Biodefense Laboratory develops, validates, and applies new technology in the field of applied diagnostics and is actively involved in training first responders and clinical laboratorians.

Dr. Peruski led international laboratory operations for the Centers for Disease Control and Prevention and spent 17 years stationed overseas developing sustainable laboratory capacity and guiding laboratory-centric public health research in more than 70 countries.

The Prusinski Lab primarily studies the ecology and epidemiology of tick-borne diseases, utilizing a combination of field and laboratory-based research methods to explore the dynamics of vector ecology and conduct tick-borne pathogen surveillance.

Annually, CLEP issues permits to approximately 1,200 clinical laboratories, 900 patient service centers and registers approximately 12,000 limited service laboratores.

We are interested in the identification of molecular markers as predictors of disease in newborns. We also focus on clinical testing, development and implementation of molecular screening methods.